| Spring Valley Health & Rehabilitation Center | |
| 2915 South Fremont Ave, Springfield, Missouri 65804 | |
| (417) 883-4022 | |
| Name | Spring Valley Health & Rehabilitation Center |
|---|---|
| Location | 2915 South Fremont Ave, Springfield, Missouri |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 194 |
| Occupancy Rate | 57.42% |
| Medicare ID (CCN) | 265188 |
| Legal Business Name | Mc Fremont Healthcare Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1104310804 |
| Organization Name | MC FREMONT HEALTHCARE, LLC |
| Address | 2915 S Fremont Ave, Springfield, MO 65804 |
| Phone Number | 417-883-4022 |
News Archive
Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.
"The Progressive Change Campaign Committee (PCCC) launched an ad urging Sen. Harry Reid to muscle through a public option as part of healthcare reform," The Hill's Blog Briefing Room reports (Zimmerman, 10/19).
The residents of southern Louisiana have all faced difficult times in the almost three years since Hurricane Katrina devastated the region. No individual, business, or community in the metropolitan New Orleans region was unscathed. Natural disasters can, and do, strike anywhere, anytime. We only have to follow the Mississippi River north to Iowa to see the devastation of floodwaters to other communities.
VENITI, Inc., a company dedicated to providing innovative technology for the treatment of venous disease, announced that it has received approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the VIRTUS trial of the VENITI VICI Venous Stent System.
There are discrepancies between the recommendations for the management of cardiovascular risk factors and their implementation in clinical practice. In the latest issue of Deutsches Ärzteblatt International, Christof Prugger and his fellow authors present the results of the EUROASPIRE I, II and III surveys in the Münster region of Germany.
› Verified 9 days ago
| NPI Number | 1144262841 |
| Organization Name | MANOR CARE OF SPRINGFIELD MO LLC |
| Doing Business As | MANORCARE HEALTH SERVICES |
| Address | 2915 S Fremont Ave, Springfield, MO 65804 |
| Phone Number | 417-883-4022 |
News Archive
Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.
"The Progressive Change Campaign Committee (PCCC) launched an ad urging Sen. Harry Reid to muscle through a public option as part of healthcare reform," The Hill's Blog Briefing Room reports (Zimmerman, 10/19).
The residents of southern Louisiana have all faced difficult times in the almost three years since Hurricane Katrina devastated the region. No individual, business, or community in the metropolitan New Orleans region was unscathed. Natural disasters can, and do, strike anywhere, anytime. We only have to follow the Mississippi River north to Iowa to see the devastation of floodwaters to other communities.
VENITI, Inc., a company dedicated to providing innovative technology for the treatment of venous disease, announced that it has received approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the VIRTUS trial of the VENITI VICI Venous Stent System.
There are discrepancies between the recommendations for the management of cardiovascular risk factors and their implementation in clinical practice. In the latest issue of Deutsches Ärzteblatt International, Christof Prugger and his fellow authors present the results of the EUROASPIRE I, II and III surveys in the Münster region of Germany.
› Verified 9 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.
"The Progressive Change Campaign Committee (PCCC) launched an ad urging Sen. Harry Reid to muscle through a public option as part of healthcare reform," The Hill's Blog Briefing Room reports (Zimmerman, 10/19).
The residents of southern Louisiana have all faced difficult times in the almost three years since Hurricane Katrina devastated the region. No individual, business, or community in the metropolitan New Orleans region was unscathed. Natural disasters can, and do, strike anywhere, anytime. We only have to follow the Mississippi River north to Iowa to see the devastation of floodwaters to other communities.
VENITI, Inc., a company dedicated to providing innovative technology for the treatment of venous disease, announced that it has received approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the VIRTUS trial of the VENITI VICI Venous Stent System.
There are discrepancies between the recommendations for the management of cardiovascular risk factors and their implementation in clinical practice. In the latest issue of Deutsches Ärzteblatt International, Christof Prugger and his fellow authors present the results of the EUROASPIRE I, II and III surveys in the Münster region of Germany.
› Verified 9 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 19.77 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 6.83 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 37.14 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.23 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0.8 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 3.55 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.19 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 93.33 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 33.99 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 67.9 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 3.51 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 41.86 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 35.73 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 8.18 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 87.76 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 70.79 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 51.66 | 82.93 |
News Archive
Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.
"The Progressive Change Campaign Committee (PCCC) launched an ad urging Sen. Harry Reid to muscle through a public option as part of healthcare reform," The Hill's Blog Briefing Room reports (Zimmerman, 10/19).
The residents of southern Louisiana have all faced difficult times in the almost three years since Hurricane Katrina devastated the region. No individual, business, or community in the metropolitan New Orleans region was unscathed. Natural disasters can, and do, strike anywhere, anytime. We only have to follow the Mississippi River north to Iowa to see the devastation of floodwaters to other communities.
VENITI, Inc., a company dedicated to providing innovative technology for the treatment of venous disease, announced that it has received approval from the United States Food and Drug Administration (FDA) for an Investigational Device Exemption (IDE) to begin the VIRTUS trial of the VENITI VICI Venous Stent System.
There are discrepancies between the recommendations for the management of cardiovascular risk factors and their implementation in clinical practice. In the latest issue of Deutsches Ärzteblatt International, Christof Prugger and his fellow authors present the results of the EUROASPIRE I, II and III surveys in the Münster region of Germany.
› Verified 9 days ago
Springfield Rehabilitation & Health Care Center Location: 2800 South Fort Avenue, Po Box 3438gs, Springfield, Missouri 65807 Phone: (417) 882-0035 | |
Wilson's Creek Nursing & Rehab Location: 3403 West Mt Vernon, Springfield, Missouri 65802 Phone: (417) 864-5600 | |
Spring Valley Health & Rehabilitation Center Location: 2915 South Fremont Ave, Springfield, Missouri 65804 Phone: (417) 883-4022 | |
Cox Medical Centers Meyer Orthopedic And Rehab Location: 3535 S National Ave, Springfield, Missouri 65807 Phone: (417) 269-9982 | |
Jordan Creek Nursing & Rehab Location: 910 South West Ave, Springfield, Missouri 65802 Phone: (417) 865-8741 | |
Glendale Gardens Nursing & Rehab Location: 3535 East Cherokee, Springfield, Missouri 65809 Phone: (417) 889-9955 |